Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement

Clinical and Translational Oncology

Volumn 14, Issue 4, 2012, Pages 280-286

  Navajas, Aurora ^a   Lassaletta, Álvaro ^b   Morales, Andrés ^c   López Ibor, Blanca ^d   Sábado, Constantino ^e   Moscardó, Cristina ^f   Mateos, Elena ^g   Molina, Javier ^h   Sagaseta, María ^h   Sastre, Ana ⁱ  

^a HOSPITAL DE CRUCES   (Spain)

^b HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^c HOSPITAL SANT JOAN DE DÉU   (Spain)

^d Montepríncipe University Hospital   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h Universidad Pública de Navarra   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Brain tumour; Intrathecal drug; Leptomeningeal disease; Paediatric

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; LIPOSOMAL CYTARABINE; LOMUSTINE; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ARACHNOIDITIS; ARTICLE; BRAIN TUMOR WITH LEPTOMENINGEAL INVOLVEMENT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUDA EQUINA SYNDROME; CENTRAL NERVOUS SYSTEM TUMOR; CHEMICAL ARACHNOIDITIS; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONSOLIDATION CHEMOTHERAPY; DISSEMINATED PINEOBLASTOMA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPENDYMOMA; FEMALE; GERM CELL TUMOR; HEMIPARESIS; HUMAN; INDUCTION CHEMOTHERAPY; INFANT; INTRACRANIAL GERMINAL TUMOR; IRRITABILITY; KARNOFSKY PERFORMANCE STATUS; LANSKY SCORE; MALE; MEDICAL RECORD REVIEW; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROECTODERM TUMOR; NEUROTOXICITY; PARESTHESIA; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RHABDOID TUMOR; SEIZURE; SIDE EFFECT; TREATMENT RESPONSE;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CYTARABINE; FEMALE; HUMANS; INFANT; LIPOSOMES; MAGNETIC RESONANCE IMAGING; MALE; MENINGEAL NEOPLASMS; PATIENT SAFETY; QUALITY OF LIFE; SPAIN; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84860747302     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0796-0     Document Type: Article

References (21)

1. Baldwin RT, Preston-Martin S (2004) Epidemiology of brain tumors in childhood: a review. Toxicol Appl Pharmacol 199:118-131 (Pubitemid 39094530)
2. Partap S, Fisher PG (2007) Update on new treatments and developments in childhood brain tumors. Curr Opin Pediatr 19:670-674 (Pubitemid 350145235)
3. Chamberlain MC (1995) A review of leptomeningeal metastases in pediatrics. J Child Neurol 10:191-199
4. Kim S, Khatibi S, Howell SB et al (1993) Prolongation of drug exposure in cerebrospinal ? uid by encapsulation into DepoFoam. Cancer Res 53:1596-1598 (Pubitemid 23113236)
5. Chamberlain MC, Kormanik P, Howell SB et al (1995) Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 52:912-917
6. Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110-3116 (Pubitemid 29470639)
7. Phuphanich S, Maria B, Braeckman R et al (2007) A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 81:201-208 (Pubitemid 44963980)
8. Angst MS, Drover DR (2006) Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Clin Pharmacokinet 45:1153-1176 (Pubitemid 44904820)
9. FDA. Depocyt Approval Letter. Available at: http://www.accessdata.fda. gov/drugsatfda-docs/ nda/99/21-041-DepoCyt-Approv.pdf. Accessed 19 May 2011
10. EMEA. Depocyte European Public Assessment Report. Available at: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Summary-for-the- public/human/000317/WC500035644. pdf. Accessed 19 May 2011
11. Bomgaars L, Geyer JR, Franklin J et al (2004) Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 22:3916-3921 (Pubitemid 41079873)
12. Slavc I, Peyrl A, Gupper A et al (2006) Tolerability of intrathecal liposomal cytarabine at a dose 25-50 mg in children 11 months to 15 years old. 7th Congress EANO in Vienna, Austria, September 14-17, 2006. Abstract 130. Available at: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid= 1871663. Accessed 8 February 2008
13. Benesch M, Sovinz P, Krammer B et al (2007) Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol 29:222-226 (Pubitemid 46597685)
14. Björgvinsdóttir H, Heldrup J, Békássy A et al (2006) Intrathecal liposomal cytarabine: clinical experience in pediatric leukemia and neuroblastoma patients. Pediatr Blood Cancer 47[Suppl 4]:444
15. Peyrl A, Sauermann R, Slavc I et al (2008) Safety and pharmacokinetics of intrathecal liposomal cytarabine (DepoCyte®) in children
16. Lassaletta A, Navajas A, Sabado C et al (2007) Intrathecal liposomal cytarabine in children with brain tumors. Presented at: 39th Annual Conference SIOP, Mumbai, India
17. Lassaletta A, Navajas A et al (2008) Intrathecal liposomal cytarabine in children with brain tumors. Presented at: SIOP 2008, 40th Annual Conference of International Society of Paediactric Oncology, Berlin, Germany
18. Lassaletta A, Perez-Olleros P, Scaglione C et al (2007) Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child. J Neurooncol 83:303-306 (Pubitemid 46952242)
19. Napp Pharmaceuticals Limited (2009) DepoCyte 50 mg suspension for injection SPC. Available at: http://emc.medicines.org.uk/document. aspx?documentId=15047. Accessed 27 February 2009
20. Sommer C, Lackner H, Benesch M et al (2008) Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia. Ann Hematol 87:887-890
21. Hospira. Cytarabine Injection Prescribing Information. Available at: http://www.hospira.com/- docs/Cytarabine%20483176-PROMOWEB.pdf.